ELAVL1 and pancreatic ductal adenocarcinoma: More recently, pyrvinium pamoate is currently in Phase I clinical trials for the treatment of pancreatic ductal adenocarcinoma in dose-escalation trials, and it has been found that its therapeutic target may be the inhibition of the nuclear cytoplasmic shuttle of HuR.